Form 4: Arcutis CFO Latha Vairavan Sells Shares for Tax Coverage

Arcutis Biotherapeutics CFO Latha Vairavan sold 1,341 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Summary

• Latha Vairavan, SVP and Chief Financial Officer of Arcutis Biotherapeutics, Inc., sold 1,341 shares of common stock.
• The transaction occurred on May 4, 2026, at a weighted average price of $23.6106 per share.
• The sale was executed to cover tax withholding obligations resulting from the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person retains beneficial ownership of 86,413 shares of common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a strategic divestment.

Positives

• The transaction was a routine sell-to-cover event rather than a discretionary divestment of equity.
• The reporting person maintains a significant remaining stake of 86,413 shares in the company.

Negatives

• The filing reflects a reduction in the direct equity holdings of a key executive.

Risks

• Reliance on Rule 10b5-1 plans for equity management is standard but subjects the executive to pre-determined sale schedules regardless of market conditions.

Future Outlook

No forward-looking guidance regarding company operations or financial performance was provided in this filing.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard industry practice for executives receiving equity-based compensation and generally do not signal a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance in the biotechnology sector.
• The use of Rule 10b5-1 plans is a common mechanism used by executives at companies like Amgen, Gilead, and other mid-cap biotechs to avoid potential insider trading concerns.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a pre-planned tax-related sale.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, CFO, Equity Vesting